Why are Moderna shares rising?
Analysts believe that Moderna shares, up a massive 115% in the last three months, are highly overvalued.
- Moderna shares closed 1.6% higher on Wednesday (15 September 2021)
- The biotech company said a new study suggests waning immunity for its vaccine
- The results point to the need for a booster dose of the mRNA-1273
- Feeling bullish or bearish about Moderna shares? Open an account with us to start trading the stock.
Moderna stock price analysis: what’s the latest?
Moderna’s stock rallied as much as 2.3% on Wednesday, after the company said there is enough data from its latest study to support the benefit of a booster vaccine dose.
Investors have been buying up Moderna shares since health authorities around the world started to discuss the efficacy of a booster shot a few months back.
Countries like the UK, US, Israel and Singapore have already started rolling out vaccine booster plans for their older residents in the coming weeks and months.
As a result of more vaccines being needed, the Moderna market capitalisation has more than doubled in the last three months.
In the last one month alone, share price has spiked up over 16%.
Despite the uptrend, the stock still has a consensus rating of ‘hold’ and a price target of only US$195.62, based on the latest analyst data published by MarketBeat.
The price target actually equates to a massive 55% potential downside from Moderna’s last traded price of US$434.50. This indicates that analysts believe the stock is severely overvalued.
The latest rating came from US investment bank SVB Leerink, which reiterated a ‘sell’ call on the stock on 12 September 2021.
'Impact of waning immunity' in vaccine
On Wednesday, the vaccine maker said 88 breakthrough cases of Covid-19 occurred in a more recently vaccinated group (49 cases per 1000 person-years) compared to 162 cases in a group vaccinated last year (77.1 cases per 1000 person-years).
The reduction in incidence rates for participants vaccinated more recently compared to participants vaccinated last year was 36%.
There were also 19 severe cases observed. Moderna said that while this was ‘not significant’, there was a ‘numerical trend towards a lower rate of severe cases’ in the group vaccinated more recently (3.3 per 1000 person-years) compared to the group vaccinated last year (6.2 per 1000 person-years).
‘The increased risk of breakthrough in this analysis quantifies the impact of waning immunity in the COVE study between the median follow-up time of 8 months and 13 months since first dose,’ the biotech company said in a press release.
‘The company believes this adds to evidence of potential benefit of a booster dose of mRNA-1273. A manuscript has been submitted as a preprint to medRxiv and will be submitted for peer-reviewed publication.’
Thinking of trading Moderna shares?
Go short and long with spread bets, CFDs and share dealing on Moderna and 16,000+ shares with the UK’s No.1 platform.* Learn more about trading shares with us, or open an account to get started today.
* Best trading platform as awarded at the ADVFN International Financial Awards and Professional Trader Awards 2019
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.